Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: 5 - The Untold Story

Johnson & Johnson Kicks Off 'Powerful New Product Cycle': Analyst

Johnson Johnson (NYSE:JNJ) on Tuesday won regulatory approval for its drug delivery product Inlexzo to treat high-risk non-muscle invasive bladder cancer, a milestone Goldman Sachs says could launch “a powerful new product cycle” for the company's TAR-200 program.

Johnson & Johnson Showcases Positive AFib Data, Treatment Results

Johnson & Johnson Showcases Positive AFib Data, Treatment Results

Johnson Johnson (NYSE:JNJ) reported new cardiovascular data at the 2025 European Society of Cardiology Congress.

Johnson & Johnson Ends Rheumatoid Arthritis Drug Combo Program

Johnson & Johnson Ends Rheumatoid Arthritis Drug Combo Program

Johnson Johnson (NYSE:JNJ) on Thursday shared topline data from the Phase 2a DAISY proof-of-concept study evaluating the combination of nipocalimab with an anti-tumor necrosis factor alpha (anti-TNFα) therapy in rheumatoid arthritis (RA) patients with refractory disease.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

How Is Johnson & Johnson’s Stock Performance Compared to Other Healthcare Stocks?

Johnson & Johnson has significantly outperformed other healthcare stocks over the past year, and analysts remain moderately bullish on the stock’s prospects.

These 2 Healthcare Stocks Are Even Better Bargain Buys Than UnitedHealth

As the healthcare sector lags broader markets, AbbVie’s innovation in immunology and Johnson & Johnson’s MedTech expansion make these dividend giants standout bargains at below-market valuations

As the Market Rotates, This Healthcare ETF Is Leading the Way

Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure.

Bridgewater, Once Led By Ray Dalio, Exits Alibaba, JD, PDD And Baidu, Dumping All US-listed Chinese Stocks Amid Geopolitical Risks

Bridgewater Associates, the world's largest hedge fund, has completely liquidated its holdings in all U.S.-listed Chinese companies, a dramatic reversal that marks the firm's most significant strategic pivot under its new post-Ray Dalio leadership.

inkl

Read news from The Economist, FT, and more,
with one subscription

3 Dividend Growth Leaders to Buy Now

3 Dividend Growth Leaders to Buy Now

Procter & Gamble, PepsiCo, and Johnson & Johnson stand out as dividend growth leaders with upside potential into year-end

JNJ Stock Surge Signals Confidence in New Growth Path

JNJ Stock Surge Signals Confidence in New Growth Path

Johnson & Johnson's strategic shift to a focused pharma and medtech model is fueling growth through a powerful drug pipeline and key acquisitions.

J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs

J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs

Johnson Johnson (NYSE:JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs proposed by the Trump administration.

Worried About a Fading Rally? Consider These 3 Dividend Stocks

Worried About a Fading Rally? Consider These 3 Dividend Stocks

Volatility is back in the markets, and jobs data points to a weakening labor market. Is it time to get defensive? Consider these 3 dividend stocks for income.

India police bust racket of fake life-saving drugs under label of top brands

India police bust racket of fake life-saving drugs under label of top brands

The counterfeit drug ring operated through an extensive network spanning multiple Indian states

The Independent UK

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Johnson & Johnson Stock: Analyst Estimates & Ratings

Johnson & Johnson Stock: Analyst Estimates & Ratings

Johnson & Johnson has outpaced the broader market and the healthcare sector in 2025, and analysts remain optimistic about the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

Drug Prices To Get 'More Expensive' Under Trump's EU Trade Deal As Pharma Faces Billions In Added Costs: Report

The pharmaceutical industry could face a significant financial hit due to the new trade deal between the U.S. and the European Union (EU), potentially leading to increased drug prices and restricted access.

3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs

On July 8, US President Donald Trump shook the biopharmaceutical sector by announcing a tariff of up to 200% on pharmaceuticals, which would take effect “very soon.” 80% of prescription drugs sold in the US are made abroad, a statistic the President wants to flip on its head.

2 Recession-Proof Dividend Stocks to Buy for the Second Half of 2025

These blue-chip stocks offer a rare combination of stability, resilience, and moderate growth.

4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise

With solid Q2 results and 2025 guidance increases, Wall Street is upgrading these four stocks. Analysts now see palpable upside in one streaming stalwart.

Get all your
news in one place.

100's of premium titles.
One news app.

Grocery Coupon Guide

10 Brand Names That Are Actually Owned By the Same Company

Ever feel like you’re making diverse choices at the grocery store or pharmacy? In reality, many of the brands you think are competitors are actually owned by the same parent company. These corporate giants dominate entire industries, using multiple brand identities to give the illusion of variety. Once you understand…

Stock Of The Day: Breakout In Johnson & Johnson

Johnson Johnson (NYSE:JNJ) stalled out at resistance around the $165 level. There tends to be resistance at price levels that had previously been resistance. As you can see on the chart below, that's the case here. This level was also resistance in March.

Want Steady Income? 3 Top Dividend Stocks for July 2025

Three dividend stocks stand out in July, offering reliable income, attractive yields, and strong fundamentals to help investors navigate market volatility

Johnson & Johnson Ups Forecast, Beats On EPS—But Wall Street Is Cautious

Shares of Johnson Johnson (NYSE:JNJ) are under pressure Thursday, despite a strong second-quarter earnings report.

Johnson & Johnson Analysts Raise Their Forecasts After Upbeat Earnings

Johnson Johnson (NYSE:JNJ) posted better-than-expected quarterly earnings and raised its FY2025 earnings guidance on Wednesday.

Rigetti Computing, Netflix, Johnson & Johnson, United Airlines And ASML: Why These 5 Stocks Are On Investors' Radars Today

U.S. stocks moved higher today, with the Dow Jones gaining more than 200 points, or 0.5%, to close at 44,254.78. The Nasdaq added 0.25% to finish at 20,730.49, while the SP 500 advanced 0.3% to 6,263.70.

JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now

Johnson & Johnson is back in rally mode after years of post-pandemic normalization and the impact of repositioning, set up to sustain higher prices for years.

1 … 4 5 6 7

People

183,712 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

The European Union

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

142,487 stories

Rheumatoid Arthritis

Places

365,390 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play